

45 (amended). The polypeptide of claim 41 in which the fragment of SEQ ID NO:2 is at least 100 amino acids in length.

~~47 (amended). A polypeptide comprising a sequence at least 85% identical to SEQ ID NO:2~~

C3 wherein said polypeptide has at least one of the following activities

- i) MASP-2 activity in an in vitro assay for MBlectin complement pathway function; or
- ii) serine protease activity; or
- iii) mannan-binding lectin (MBL) associating activity.

~~55 (amended). The polypeptide of any one of claims 41-46, 48, 54 in which the polypeptide is characterized by at least one of the following activities:~~

- C4
- a. ability to associate with mannan-binding lectin;
  - b. serine protease activity or cleavage of complement factor C2 or C4;
  - c. MASP-2 activity in an in vitro assay for MBlectin complement pathway function;
  - d. competitive inhibition of one of a.-c. above.

#### REMARKS

1. Claim 46 has been allowed. Claims 11 and 41 have been rewritten in independent form, and therefore should be allowable.<sup>1</sup> Likewise, claims 42-45 are now dependent on claim 41. Claim 47 has been amended to recite a biological activity, per claim 55. Claims 49-53 were previously made dependent on 47; the dependencies of claim 55 have been adjusted accordingly.

2. The anticipation rejection of claim 40 is moot as that claim has been cancelled.

---

<sup>1</sup> Claim 11 refers to SEQ ID NO:2. Its base claim (4) referred to SEQ ID NO:1. SEQ ID NO:1 is a portion of SEQ ID NO:2, beginning at AA 16. Reference to SEQ ID NO:1 is therefore unnecessary.